Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes

Next Previous
X
Search
Trial Profile

A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mazdutide (Primary) ; Dulaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 24 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2023 Results published in the Diabetes Care.
    • 18 Jul 2022 Primary endpoint (The change in HbA1c from baseline to 20 weeks) has been met, according to an Innovent Biologics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top